Lamivir: Each film coated tablet contains Lamivudine INN 100 mg.
Lamivudine is a synthetic nucleoside analogue with activity against Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV).
Lamivir is indicated for the treatment of chronic hepatitis B associated with evidence of hepatitis B viral replication and active liver inflammation.
The recommended dose of Lamivudine for the treatment of chronic hepatitis B in adults is 100 mg once daily. The recommended dose for pediatric patients of 2 to 17 years of age is 3 mg/kg once daily up to a maximum daily dose of 100 mg. Treatment should be continued if there is no loss of efficacy and until adequate seroconversion is achieved.
Nausea, vomiting, diarrhoea, abdominal pain, cough, headache, insomnia, malaise, fever, rash, alopecia, muscle disorders, nasal symptoms, peripheral neuropathy may occur. Sometimes neutropenia and anemia; thrombocytopenia; lactic acidosis, raised liver enzymes and serum amylase have been reported.
Patients should be assessed before giving treatment with Lamivudine. Safety and efficacy of Lamivudine have not been established in patients with decompensated liver disease, pediatric patients, patients dually infected with Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV), Hepatitis Delta. Reduction in dosage is recommended for patients with impaired renal function.
There are no adequate and well controlled studies in pregnant woman. Lamivudine should be used in pregnancy if the potential benefits outweigh the risks. Mother should be instructed not to breastfeed if they are receiving Lamivudine.
Lamivir : Each box contains 2 blister strips of 10 tablets.